Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has signed a Letter of Intent (“LOI”) with Pharmaflorx Ltd. (“PFX”) for the supply of cannabis oils and isolates. PFX is a privately-held late-stage Access to Cannabis for Medical Purposes Regulations (“ACMPR”) applicant located in Gatineau, Quebec. Per the update, Pivot will acquire a minimum of 1,000 kg/year of cannabis oils or isolates from PFX to manufacture its patented portfolio of biocannabis products. Pivot intends to supply both the Canadian and European Union markets with its suite of patented products following receipt of fitting licenses where regulations permit. “We welcome Pharmaflorx to our growing list of strategic partners and look forward to collaborating with their team to provide a steady and consistent supply of premium cannabis oils and isolates for Pivot’s portfolio of products,” Pivot CEO Dr. Patrick Frankham stated in the news release. “We continue to execute aggressively on our business plan to bring Pivot’s industry leading pipeline of derivatives to market by the end of this year.”
To view the full press release, visit http://ibn.fm/k9VJs
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, will manufacture and supply finished powderized cannabis products such as food additives, capsules, bulk powder and stick packs to the California market. PGS has acquired worldwide rights to Ready-To-Infuse Cannabis (“RTIC”) oil-to-powder technology, BiPhasix™ Dermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (“CBD”), and tetrahydrocannabinol (“THC”)-based products. For more information, visit the company’s website at www.PivotPharma.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
